Clinical Study of Transcriptome-based Diagnostic Biomarker for Acute Febrile Illness

NCT ID: NCT06552975

Last Updated: 2024-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

900 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-01

Study Completion Date

2025-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute febrile illness is the main cause of outpatient visits,and bacterial and viral infections remains the most common cause. The diagnosis of infection is still based on symptoms and traditional techniques, resulting in overuse of antibacterial drugs or delay in treatment. The signature of host transcripts has a potential to reveal different modes of host-pathogen interaction and may serve as a biomarker for infection discrimination. Of note, transcriptome-microarray and RNA-seq methods need sophisticated techniques and expertise interpretation, hampering the universal implement of these platforms in low-tier hospitals and under- resourced countries. This study explores transcriptome-based diagnostic biomarker for acute febrile illness , hoping to achieve rapid, accurate and cost-effective distinction between bacterial and viral infection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute fever is a common medical emergency worldwide, most often caused by bacterial or viral infections. Early and rapid differential diagnosis of infectious diseases is crucial for improving patient outcomes. While pathogen detection remains the gold standard for diagnosing infections, methods like culture are time-consuming and often lack sensitivity. Additionally, the presence of normal colonizing microorganisms, such as bacteria and viruses in the human body, can lead to false positives in pathogen detection. These limitations often compel physicians to rely on empirical antibacterial therapy based on clinical symptoms, inadvertently contributing to antibiotic overuse and the growing problem of bacterial resistance.

Furthermore, the misuse of antibacterial drugs in patients with non-bacterial infections can lead to complications such as secondary infections with Clostridium difficile, liver dysfunction, kidney damage, cytopenia, and alterations in the body's microbiota. Diagnostic markers based on host inflammatory responses offer an alternative approach to infection diagnosis. However, protein biomarkers like procalcitonin, though widely used in clinical settings, are far from ideal for accurately diagnosing bacterial infections, as they are prone to false positives and negatives.

A promising direction is the analysis of host-pathogen interactions at the transcriptome level, particularly the differential gene expression of the host in response to various pathogens. This area of research has gained significant attention recently. Transcriptomic markers derived from patients' peripheral blood have been successfully utilized in diagnosing and studying the pathogenesis of various infectious diseases.

Despite these advances, studies relying on RNA sequencing or transcriptome chip technology require specialized equipment and bioinformatics expertise, making them expensive and challenging to implement in routine clinical practice. Additionally, the results from transcriptome analysis are not easily validated by reverse transcription polymerase chain reaction(RT-PCR), the "gold standard" for RNA quantification. Therefore, to make transcriptome-based diagnostic markers more clinically applicable, there is a need for real-time technologies, such as PCR, to enhance the accuracy of infection diagnosis and reduce the misuse of antibacterial drugs. Currently, research in this area remains limited.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Febrile Illness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bacterial infection

Individuals with acute fever whose positive bacteria isolated from sterile or non-sterile sites have pathological characteristics.

Infection

Intervention Type OTHER

Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.

Viral infection

Individuals with acute fever whose viral nucleic acid test and/or serological positive compatible with acute syndrome#(e.g. serology, PCR).

Infection

Intervention Type OTHER

Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.

non-infectious group

Individuals with acute fever whose have negative findings in cultures and PCR; negative image modality findings suspected for infection; confirmed or highly likely other diagnosis; improvement without antibiotics.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Infection

Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. axillary temperature ≥38°C; 2. duration of fever shorter than 14 days; 3. subjects who are fully informed and agree to participate in this study.

Exclusion Criteria

* 1.having comorbidities that may affect host gene expression, such as advanced malignancy, autoimmune diseases,immunodeficiency, or taking immune suppressors; 2.pregnancy; 3. mixed infection (viral combined with bacterial infection, autoimmune disease combined with bacterial infection); 4.incomplete clinical information; 5. For safety reasons or the interests of patients, clinicians believe that patients should not participate in any situation in this study.
Minimum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Qilu Hospital of Shandong University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gang Wang

Role: STUDY_DIRECTOR

Qilu Hospital of Shandong University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Qilu Hospital of Shandong University

Jinan, Shandong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gang Wang, professor

Role: CONTACT

86-18560082130

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gang Wang

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KYLL-202008-058

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.